GSK2982772
RIP1 inhibitor / GSK2982772 is a highly selective inhibitor of Receptor-interacting Protein 1 kinase (RIP1); IC50 = 1.6 nM.1 Novel anti-inflammatory agent previously in clinical trials for psoriasis, rheumatoid arthritis, and ulcerative colitis.2,3
Biochemicals & reagents
1622848-92-3
1) Harris et al. (2017), Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases; J. Med. Chem. 60 1247 2) Weisel et al. (2017), Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers; Pharmacol. Res. Perspect. 5 e00365 3) Lu et al. (2020), RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk; Biochem. Pharmacol. 172 113751
-20°C
TARGET: Kinase -- PATHWAY: TNF; Cytokine -- RESEARCH AREA: Cell death -- DISEASE AREA: Inflammation